Clinical trial
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With…
NCT00072046 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00072046 |
|---|---|
| Title | Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) |
| Official title | A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH NCIC Clinical Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | bevacizumab, recombinant interferon alfa |
| Enrollment | 732 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 1, 2004 |
| Completion | Nov 1, 2012 |
| First posted | Nov 6, 2003 |
| Last update posted | Jul 6, 2016 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: